Seizert Capital Partners, LLC Exelixis, Inc. Transaction History

Seizert Capital Partners, LLC

$2.16 Billion
Q3 2024

A detailed history of Seizert Capital Partners, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Seizert Capital Partners, LLC holds 469,940 shares of EXEL stock, worth $15.6 Million. This represents 0.57% of its overall portfolio holdings.

Number of Shares

469,940

Previous 435,065 8.02%

Holding current value

$15.6 Million

Previous $9.78 Million 24.75%

% of portfolio

0.57%

Previous 0.5%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	BUY	$21.96 - $27.6 $765,855 - $962,550	34,875 Added 8.02%	469,940 $12.2 Million
Q2 2024 Aug 07, 2024	BUY	$20.34 - $23.73 $316,958 - $369,784	15,583 Added 3.71%	435,065 $9.78 Million
Q1 2024 May 01, 2024	SELL	$20.17 - $23.93 $17,205 - $20,412	-853 Reduced 0.2%	419,482 $9.95 Million
Q4 2023 Feb 07, 2024	SELL	$19.25 - $24.13 $834,275 - $1.05 Million	-43,339 Reduced 9.35%	420,335 $10.1 Million
Q3 2023 Nov 06, 2023	BUY	$19.04 - $22.74 $224,576 - $268,218	11,795 Added 2.61%	463,674 $10.1 Million
Q2 2023 Jul 27, 2023	SELL	$18.17 - $20.48 $716,733 - $807,854	-39,446 Reduced 8.03%	451,879 $8.64 Million
Q1 2023 May 09, 2023	SELL	$16.3 - $19.41 $401,729 - $478,378	-24,646 Reduced 4.78%	491,325 $9.54 Million
Q4 2022 Jan 30, 2023	BUY	$14.96 - $17.39 $1.62 Million - $1.88 Million	108,221 Added 26.54%	515,971 $8.28 Million
Q3 2022 Nov 02, 2022	SELL	$15.68 - $22.27 $4,217 - $5,990	-269 Reduced 0.07%	407,750 $6.39 Million
Q2 2022 Aug 04, 2022	SELL	$17.44 - $23.16 $38,350 - $50,928	-2,199 Reduced 0.54%	408,019 $8.5 Million
Q1 2022 May 03, 2022	SELL	$17.03 - $22.67 $95,368 - $126,952	-5,600 Reduced 1.35%	410,218 $9.3 Million
Q4 2021 Feb 08, 2022	SELL	$15.84 - $21.88 $1.92 Million - $2.66 Million	-121,344 Reduced 22.59%	415,818 $7.6 Million
Q3 2021 Nov 03, 2021	BUY	$16.3 - $21.14 $2.69 Million - $3.49 Million	165,042 Added 44.35%	537,162 $11.4 Million
Q2 2021 Aug 05, 2021	SELL	$17.95 - $25.56 $382,927 - $545,271	-21,333 Reduced 5.42%	372,120 $6.78 Million
Q1 2021 May 05, 2021	BUY	$20.53 - $25.22 $8.08 Million - $9.92 Million	393,453 New	393,453 $8.89 Million

Others Institutions Holding EXEL

# of Institutions

502

Shares Held

243M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Seizert Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Seizert Capital Partners, LLC with notifications on news.

Account

Seizert Capital Partners, LLC Exelixis, Inc. Transaction History